論文

査読有り 国際誌
2016年4月

Sonodynamic therapy using 5-aminolevulinic acid enhances the efficacy of bleomycin.

Ultrasonics
  • Tomohiro Osaki
  • ,
  • Misato Ono
  • ,
  • Yoshihiro Uto
  • ,
  • Masahiro Ishizuka
  • ,
  • Tohru Tanaka
  • ,
  • Nobuyasu Yamanaka
  • ,
  • Tsukasa Kurahashi
  • ,
  • Kazuo Azuma
  • ,
  • Yusuke Murahata
  • ,
  • Takeshi Tsuka
  • ,
  • Norihiko Ito
  • ,
  • Tomohiro Imagawa
  • ,
  • Yoshiharu Okamoto

67
開始ページ
76
終了ページ
84
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.ultras.2016.01.003

Sonodynamic therapy (SDT) kills tumor cells through the synergistic effects of ultrasound and a sonosensitizer agent. We examined whether 5-aminolevulinic acid (5-ALA)-based SDT at 1 or 3 MHz could enhance the cytotoxicity of bleomycin (BLM) toward mouse mammary tumor cells both in vitro and in vivo. At 1 MHz, cell viability in the 5-ALA-based SDT group at 1, 2, and 3 W/cm(2) was 34.30%, 50.90%, and 60.16%, respectively. Cell viability in the 5-ALA-based SDT+BLM group at 1, 2, and 3 W/cm(2) was 0.09%, 0.32%, and 0.17%, respectively. In contrast, at 3 MHz, 5-ALA-based SDT+BLM did not show pronounced cytotoxicity. In the in vivo study, 5-ALA-based SDT+BLM was significantly more cytotoxic than 5-ALA-based SDT at 1 MHz and 3 MHz. These findings suggest that the mechanism of tumor shrinkage induced by 5-ALA-based SDT+BLM might involve not only direct cell killing, but also vascular shutdown. Thus, we show here that 5-ALA-based SDT enhances the efficacy of BLM both in vitro and in vivo.

リンク情報
DOI
https://doi.org/10.1016/j.ultras.2016.01.003
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26799128
ID情報
  • DOI : 10.1016/j.ultras.2016.01.003
  • PubMed ID : 26799128

エクスポート
BibTeX RIS